Compound
Everything we've written on Bremelanotide — 9 articles covering the mechanism, the evidence, comparisons, and practical considerations.
9 articles
Origins and discoveryMelanotan II and the bodybuilding split — how a tanning research peptide became a libido drugThere is a particular category of scientific discovery that gets described, with some frequency, as accidental. The word undersells what usually happened, which is not randomness but observation: someone noticed something unexpected and, instead of explaining it away, wrote it down and asked what it meant. The discovery that launched Melanotan II's trajectory from research compound to gray-market phenomenon falls into that category. The researchers were looking for tanning. They found something else first.8 min readSexual healthPeptides for libido and sexual health — what research has explored beyond ViagraIt is not always about arousal in the moment. Sometimes it is about desire that used to be there and now isn't. A kind of flatness that sits behind the physical — you can engage, sometimes, but the wanting-to isn't present in the way it once was. It might have come on gradually, over months, and it took a while to name it as a change rather than just a mood. Or it is more specific: physical function is fine but the internal experience feels disconnected. Or the inverse — desire is present but the body is not cooperating the way it should. These are different problems. They have different mechanisms and, as a result, different possible interventions.10 min readSexual healthWhat people are reporting about PT-141 — side effects, dose timing, what works and what doesn'tThis article summarizes experiences reported in public online communities including Reddit, longevity forums, and discussion boards. We are not advocating human use of any compound discussed here. Many of the peptides discussed are not FDA-approved for the uses described, and some are explicitly not approved for human or veterinary use. What follows is a synthesis of what people have reported, presented to give readers context on the public conversation — not as guidance, not as evidence of safety or efficacy, and not as a recommendation. Decisions about any compound should be made with a qualified prescribing provider after a full medical evaluation.8 min readSexual healthPT-141 in men — what off-label research has exploredYou've had your testosterone checked. It came back normal. Your doctor said there was nothing wrong. But something is different from five years ago — not dramatically different, not obviously broken, just quieter. The interest arrives less reliably. The arousal that used to be almost automatic now requires more from you, more effort, more right circumstances, and sometimes doesn't fully show up even then. Viagra works, in the sense that the mechanics work when you use it. But Viagra wasn't the question. The question was why you needed it, and nobody has answered that.8 min readSexual healthPT-141 in plain English — how a brain melanocortin agonist became a libido drugYou're not in the mood. Not because anything is wrong, exactly. Not because of a fight, or exhaustion, or a specific stressor you can name. Just — absent. The interest isn't there. And the absence is its own kind of problem, because desire isn't something you can manufacture by deciding to want it. You can go through the motions. You can create conditions. But the signal either arrives or it doesn't, and if it doesn't, nothing downstream can substitute for it.8 min readOrigins and discoveryPT-141 — the peptide that was supposed to be a tanning drugIt was 1980-something in a University of Arizona lab, and a pharmacologist named Mac Hadley had a genuinely reasonable idea: if sunlight causes melanin production by triggering alpha-melanocyte-stimulating hormone, could you give people a synthetic version of that hormone and let them tan without UV exposure? Protect skin from cancer by inducing its own protection. The logic was clean. The molecule they needed — a synthetic analog of α-MSH — was the kind of thing Victor Hruby's lab was built to design.8 min readSexual healthPT-141 stacking — what people combine and what the evidence suggestsThe question comes up in clinical contexts more often than people might expect. Someone is using PT-141 — or its pharmaceutical equivalent, Vyleesi — and wants to know whether combining it with something else would work better. Or they're working with a provider who has prescribed PT-141 as part of a broader protocol and is thinking about what else belongs in that picture. The stacking conversation around PT-141 reflects a real clinical need: sexual dysfunction is usually multifactorial, and a single mechanism rarely captures the whole problem.7 min readSexual healthPT-141 vs PDE5 inhibitors (Viagra, Cialis) — different drug, different systemThe conversation at the pharmacy counter, or more often now on the app that ships pills in discrete packaging, usually goes like this: you want something for sexual function, the question is which one, and the answer comes in terms of timing and duration and whether you need it as-needed or daily. Four hours vs. thirty-six hours. Generic or brand. That's the decision tree as most people experience it.7 min readSexual healthVyleesi and the FDA approval — what the trials showedThe FDA receives a lot of drug applications. Most of them fail, or succeed, or somewhere between those poles arrive at a narrowly worded approval that takes years longer than anyone hoped. The approval of bremelanotide as Vyleesi in June 2019 was notable not because of its commercial promise — which has been limited — but because of what it represented: the first on-demand pharmacological treatment for hypoactive sexual desire disorder in premenopausal women, approved on the strength of two Phase III trials, after a development path that had started with accidental erections in a tanning study and spent twenty years finding its footing.8 min read